Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Venture capital firm investing in early-stage biotechnology and life science companies, focused on healthcare innovation.
Alta Partners is a venture capital firm focused on early-stage biotechnology, life sciences, and healthcare technology companies, based in San Francisco and Denver. The firm has managed over $2.6 billion in total capital across nine funds, investing in more than 150 companies that have collectively achieved over 100 FDA approvals. Throughout its history, the organization has recorded more than 114 mergers, acquisitions, and initial public offerings, generating returns through management fees and carried interest. Recently, the firm closed its Alta Partners NextGen Fund III with $275 million in capital commitments to deploy into therapeutics and digital health startups. The firm's investment portfolio features several clinical-stage biopharmaceutical and medical innovation companies, including Kite Pharma, Allakos, Esperion Pharmaceuticals, and eGenesis. Alta Partners was founded in 1996 by Jean Deleage, Garrett Gruener, Marino Polestra, and Dan Janney.
Key people at Alta Partners.
Key people at Alta Partners.
Alta Partners is a healthcare-focused venture capital firm founded in 1996, specializing in early-stage investments in life sciences and tech-enabled healthcare services. Their mission centers on building high-impact companies that improve patient outcomes by leveraging innovation and technology in healthcare. They maintain a disciplined investment philosophy focused on trust, focus, and impact, managing small, concentrated portfolios to provide dedicated support to each company. Alta Partners primarily invests in sectors such as biotechnology, health tech, medical devices, and data science, contributing significantly to the startup ecosystem with over 75 FDA-approved products emerging from their portfolio and tech-enabled services reaching hundreds of thousands of patients annually[1][2][3].
The firm was established by four senior partners from Burr, Egan, Deleage & Co.—Jean Deleage, Guy Nohra, Garrett Gruener, and Marino Polestra—who brought decades of experience in early-stage investing in life sciences and technology. Over time, Alta Partners has evolved by raising multiple venture funds, including the NextGen Funds launched in 2017, which total over $800 million and support tailored portfolios aimed at partnering with leading entrepreneurs. The firm’s history includes successful exits and FDA approvals for portfolio companies, reflecting its deep expertise and commitment to healthcare innovation[1][2].
Alta Partners rides the wave of healthcare innovation driven by advances in biotechnology, medical devices, and digital health. The timing is critical as healthcare systems increasingly integrate technology to improve patient outcomes and reduce costs. Market forces such as regulatory support for novel therapies, rising healthcare demands, and digital transformation favor their investment focus. By backing transformative startups, Alta Partners influences the broader ecosystem by accelerating the development and commercialization of breakthrough healthcare solutions[1][3].
Looking ahead, Alta Partners is positioned to continue driving innovation in healthcare through its NextGen Funds and sustained focus on early-stage companies. Trends such as gene therapy, AI in healthcare, and personalized medicine will likely shape their investment strategy. Their influence is expected to grow as they support the next generation of entrepreneurs developing therapies and technologies that could redefine patient care. Alta Partners’ commitment to trust, focus, and impact ensures it remains a key player in advancing healthcare innovation[1][2][3].
Alta Partners has more than 26 tracked investments across 20 companies. The latest tracked deal is $20.0M Other Equity in Finch Legal in October 2025.
